Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8229340 | 0.86 | NPY5R (0.42) | NPY5RHSD17B3TSHRCHRM1LMNA | |
| SCHEMBL8228878 | 0.86 | HSD17B3 (0.39) | HSD17B3LMNAMAPTMEN1KMT2A | |
| SCHEMBL8267925 | 0.86 | SIGMAR1 (0.45) | HSD17B3TSHRCHRM1LMNAMAPT | |
| SCHEMBL8229312 | 0.84 | CNR2 (0.44) | NPY5RHSD17B3LMNAMEN1KMT2A | |
| SCHEMBL13668171 | 0.83 | LMNA (0.57) | HSD17B3LMNAMAPTMEN1KMT2A | |
| SCHEMBL4327026 | 0.83 | NPSR1 (0.49) | TSHRCHRM1LMNASIGMAR1 | |
| SCHEMBL8006581 | 0.81 | NPY5R (0.41) | NPY5RHSD17B3TSHRCHRM1LMNA | |
| SCHEMBL4326972 | 0.81 | HDAC1 (0.54) | — | |
| SCHEMBL4331304 | 0.78 | NPSR1 (0.51) | NPY5RHSD17B3TSHRLMNAMAPT | |
| SCHEMBL30808640 | 0.78 | KMO (0.55) | NPY5RHSD17B3TSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | claimed |
| US-20080269204-A1 | Compounds and Methods of Use Thereof | DYAKONOV TATYANA | 2008-10-30 | — | — | US | claimed |
| WO-2007134169-A9 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA LLC (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2006050054-A2 | COMPOUNDS AND METHODS OF USE THEREOF | NUADA, LLC (US) | 2006-05-11 | — | — | WO | claimed |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20080269204-A1 | Compounds and Methods of Use Thereof | DYAKONOV TATYANA | 2008-10-30 | — | — | US | disclosed |
| US-20080269204-A1 | Compounds and Methods of Use Thereof | DYAKONOV TATYANA | 2008-10-30 | — | — | US | disclosed |
| US-20080269204-A1 | Compounds and Methods of Use Thereof | DYAKONOV TATYANA | 2008-10-30 | — | — | US | disclosed |
| WO-2007134169-A9 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA LLC (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2006050054-A2 | COMPOUNDS AND METHODS OF USE THEREOF | NUADA, LLC (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006050054-A2 | COMPOUNDS AND METHODS OF USE THEREOF | NUADA, LLC (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269204-A1 | Compounds and Methods of Use Thereof | TNF, LITAF, TNFRSF1A | NPY5R 2155/4885HSD17B3 2562/4885TSHR 3277/4885 |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | TNF, NFKBIA, IL6 | NPY5R 2140/4885HSD17B3 2824/4885TSHR 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.